SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Classover Holdings entered into a ChEF Purchase Agreement with Chardan Capital Markets LLC providing the right to issue and sell up to $100 million in newly issued shares of Class B common stock at a 4.0% discount to volume-weighted average price, subject to Nasdaq Exchange Cap limitations (19.99% of outstanding shares) and beneficial ownership caps (4.99%-9.99%).
View raw filing on EDGAR →The filing discloses the Company's failure to comply with a Market Capitalization Covenant under senior secured convertible notes totaling $9.9 million, triggering a 10% penalty on outstanding principal and granting the lender conversion rights. Although a waiver was obtained, the underlying breach of a material debt covenant is the principal disclosed event and represents a significant financial stress indicator for a reasonable investor.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the Company's May 20, 2026 annual meeting of shareholders. The filing reports final voting tallies for two proposals: (1) election of nine directors to the Board, with detailed vote counts and percentages for each nominee, and (2) an advisory vote to approve named executive officer compensation, which passed with 98.05% approval. This is a textbook Item 5.07 disclosure of shareholder meeting results, which is material to investors as it confirms board composition and executive compensation approval.
View raw filing on EDGAR →LyondellBasell held its Annual Meeting of shareholders on May 22, 2026, with voting results on nine proposals including director elections, auditor appointments, executive compensation advisory vote, and authorization of a share repurchase program of up to 10% of issued share capital (34,042,250 shares) through November 22, 2027.
View raw filing on EDGAR →Shareholders approved amendments to the LyondellBasell Industries Long Term Incentive Plan, authorizing an additional 8,000,000 ordinary shares for issuance and establishing per annum grant limits of $2 million for non-executive directors.
View raw filing on EDGAR →This 8-K discloses the results of Trio Petroleum's annual meeting of stockholders held on May 21, 2026, under Item 5.07. The filing reports voting outcomes on four proposals: election of a Class III director (Robin Ross), approval of a reverse stock split (1:2 to 1:10 ratio), amendment to the 2022 Equity Incentive Plan to increase reserved shares by 3.5 million, and ratification of Bush & Associates CPA LLC as independent auditor. All proposals passed by majority vote, making this a standard shareholder vote results disclosure.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from MAIA Biotechnology's 2026 Annual Meeting held on May 21, 2026, filed under Item 5.07. The filing reports voting outcomes for two proposals: (1) election of Class I directors (Louie Ngar Yee and Steven Chaouki re-elected) and (2) ratification of Grant Thornton LLP as independent auditor, with specific vote tallies for each matter. This is a routine but material governance disclosure required by Item 5.07.
View raw filing on EDGAR →The filing discloses that Cayson Acquisition Corp's insiders deposited a $125,000 contribution on May 21, 2026, as the third monthly installment required under a shareholder-approved extension of the business combination deadline to March 23, 2027. While this relates to a SPAC's extension mechanism and insider funding, it does not cleanly fit the standard taxonomy categories (not an M&A completion, not a shareholder vote result per se, not a covenant breach). The contribution to the trust account is material to investors assessing the company's runway and commitment to completing a business combination, but the event is primarily administrative in nature—a routine funding deposit under a previously approved extension plan.
View raw filing on EDGAR →Item 3.01 discloses that GT Biopharma received notice from Nasdaq on May 20, 2026, granting an additional 180-day compliance period (until November 16, 2026) to regain compliance with the minimum bid price requirement of $1.00 per share. The company's stock had previously fallen below this threshold for 30 consecutive business days. This is a classic delisting risk disclosure—the company faces potential removal from Nasdaq if it cannot restore its stock price above $1.00 within the extended cure period.
View raw filing on EDGAR →The filing discloses the appointment of Tyler Evans, Chief Investment Officer, as a Class II director on May 21, 2026, following Board approval to expand from six to seven directors. While the filing also covers a 1-for-40 reverse stock split (Item 5.03), the substantive executive action is the director appointment. Evans will not receive additional compensation and does not qualify as independent, but the appointment itself is a material change to Board composition that would affect investor assessment of governance.
View raw filing on EDGAR →Mr. Paul Stuka, the current Chair of the Board and Chair of the Compensation Committee, notified the Company on May 20, 2026 of his decision to not seek reelection and to retire from the Board at the 2027 Annual Meeting. This is a material departure of a senior director and board leadership position, disclosed under Item 5.02.
View raw filing on EDGAR →The filing discloses under Item 4.01 that Integrität Audit, Accounting & Advisory, LLC resigned as the independent registered public accounting firm on May 19, 2026, without completing the audit for fiscal year ended December 31, 2025. Simultaneously, M&K CPAs, PLLC was appointed as the new independent registered public accounting firm on May 21, 2026. This is a classic auditor change event material to investors assessing financial reporting reliability.
View raw filing on EDGAR →Akari Therapeutics entered into a securities purchase agreement on May 20, 2026 to sell 1,470,588 unregistered ADSs (or pre-funded warrants) plus multiple series of warrants in a private placement for approximately $5.5 million gross proceeds. This unregistered equity issuance under Section 4(a)(2) and Regulation D includes significant warrant coverage that will further dilute shareholders upon exercise.
View raw filing on EDGAR →Peace Acquisition Corp is a SPAC (special purpose acquisition company) that has completed its initial public offering on May 21, 2026, as evidenced by the effective Registration Statement on Form S-1 and the entry into material definitive agreements including underwriting agreements, warrant agreements, and private placement purchase agreements. While the filing is technically structured as Item 1.01 (Entry into Material Definitive Agreement), the substance reflects the foundational transaction of a SPAC formation and IPO, which constitutes material acquisition-related activity under the taxonomy's ma_activity category.
View raw filing on EDGAR →Mike Powell's departure from his role as Chief Innovation Officer, effective May 29, 2026, is the principal disclosed event. The filing explicitly states the departure date and the notice received on May 18, 2026. As a C-suite officer responsible for technology leadership, this departure is material to investors assessing the company's executive stability and strategic direction, particularly given the company's reference to providing an update on "enhanced technology leadership" at its June 15 earnings call.
View raw filing on EDGAR →Ensysce Biosciences received notice from Nasdaq on May 21, 2026, that it is subject to delisting due to non-compliance with the $2.5 million stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The company has 45 days to submit a compliance plan or face delisting, with a potential 180-day extension if the plan is accepted. This is a classic delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →Item 2.02 discloses a press release issued on May 18, 2026 announcing financial results for the quarter ending March 31, 2026, along with operational highlights. The filing explicitly references the press release as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, which is material to investors as it provides quarterly financial performance and operational updates.
View raw filing on EDGAR →The filing discloses a Nasdaq notice of non-compliance with Listing Rule 5250(c)(1) due to failure to timely file the Form 10-Q for the period ended March 31, 2026. While the notice has no immediate effect on listing, the company has 60 calendar days to submit a compliance plan or face potential delisting. This is a material disclosure of delisting risk under Item 3.01.
View raw filing on EDGAR →The filing discloses a settlement agreement under which FOXO Technologies issued 400 shares of Series D Preferred Stock (convertible into Class A Common Stock) plus $175,000 in cash payments to J.H. Darbie & Co., Inc. Item 3.02 explicitly addresses "Unregistered Sales of Equity Securities" and notes the issuance was made under Section 4(a)(2) and Regulation D. The convertible preferred stock and potential conversion of unpaid cash balances into common stock at 90% of VWAP represent dilutive equity issuances typical of settlement arrangements at smaller issuers.
View raw filing on EDGAR →The filing discloses entry into a Third Amendment to Securities Purchase Agreement and Junior Convertible Notes on May 22, 2026, which materially amends the terms of convertible debt instruments. The amendments include deferral of installment payments to July 2026, addition of anti-dilution provisions, removal of redemption requirements, and extension of investor participation rights to December 2027. While this is a debt restructuring rather than a traditional M&A transaction, it represents a material definitive agreement under Item 1.01 that would affect investor assessment of the company's capital structure and financial obligations.
View raw filing on EDGAR →The filing discloses the appointment of Theodore P. Botts as a member of the Board of Directors on May 19, 2026, to fill a vacancy. The disclosure includes his extensive background in investment banking and finance, and the Company entered into a Director Agreement and Indemnification Agreement providing for an annual fee of $75,000 payable in shares. This is a material executive appointment affecting the composition and governance of the registrant's board.
View raw filing on EDGAR →Laser Photonics received a notice from Nasdaq on May 21, 2026, stating non-compliance with continued listing rules due to failure to file the Form 10-Q for the period ended March 31, 2026. The company has 60 days to submit a compliance plan, with a maximum 180-day cure period ending November 16, 2026. This is a direct delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →The filing discloses a delinquency compliance alert from Nasdaq on May 21, 2026, advising that Global Interactive Technologies is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q for Q1 2026 and its Form 10-K for 2025. The company has until October 12, 2026 to regain compliance, with a required update to its compliance plan by June 22, 2026. This is a classic delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →The filing discloses multiple material transactions on May 21, 2026: (1) issuance of convertible notes totaling $970,600 principal ($807,100 net proceeds) to CFI Capital and Monroe Street Capital with conversion rights at 80% of VWAP, reserving 2,206,434 shares; (2) a Services Agreement with Mammoth Crest Capital granting 4.5% equity stake plus $500,000 in cash fees; and (3) a Side Letter requiring shareholder approval for issuances exceeding the 19.99% Exchange Cap. These unregistered equity issuances under Section 4(a)(2) are highly dilutive and material to investors assessing ownership and capital structure.
View raw filing on EDGAR →The filing discloses issuance of 535,000,000 shares of common stock to officers, directors, and consultants pursuant to the 2026 Equity Incentive Plan and an effective Form S-8 registration statement. This represents a massive dilutive equity issuance that would materially affect shareholder ownership and is a strong signal of capital structure change typical of small-cap companies raising resources or compensating insiders.
View raw filing on EDGAR →The filing discloses BJ's Wholesale Club's financial results for the first quarter of fiscal year 2026 ended May 2, 2026, via a press release furnished as Exhibit 99.1. This is a standard quarterly earnings release disclosure under Item 2.02, which is material to investors as it provides periodic financial performance information.
View raw filing on EDGAR →The disclosure centers on the compensation committee's grant of stock options to named executive officers (Wade Black, CFO, and Phillip Nickerson, VP of Exploration) under the 2022 long-term incentive plan. The specific terms—exercise price, vesting schedule, and number of shares—are classic equity compensation arrangements that materially affect executive remuneration and would influence investor assessment of management incentives.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the May 21, 2026 Annual Meeting of Stockholders, filed under Item 5.07. The filing reports final vote tallies for four proposals: election of two Class II directors (Sara Baack and Ligia Torres Fentanes), approval of amendments to the 2006 Stock Incentive Plan, advisory approval of executive compensation, and ratification of KPMG LLP as independent auditor. All proposals passed with substantial majorities, making this a routine but material annual meeting disclosure.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Eve Holding's 2026 Annual Meeting of Stockholders held on May 21, 2026. The filing presents voting results for four proposals: election of Class I directors (Sergio Pedreiro and Uallace Moreira Lima), advisory approval of NEO compensation, frequency of future advisory votes on compensation (approved for every three years), and ratification of KPMG LLP as independent auditor. All proposals passed with substantial majorities, making this a routine but material shareholder vote results disclosure.
View raw filing on EDGAR →Zoetis held its Annual Meeting of Shareholders on May 20, 2026, with voting results on five proposals: election of twelve directors, advisory votes on executive compensation and frequency thereof, ratification of KPMG LLP as independent auditor, and a shareholder proposal on written consent.
View raw filing on EDGAR →AH Realty Trust completed the disposition of nine multifamily properties for approximately $485.0 million in aggregate proceeds on May 20, 2026, as the first closing under a larger $562.0 million multifamily disposition agreement entered into on March 13, 2026. Two additional properties are expected to close by mid-2027.
View raw filing on EDGAR →The filing discloses Amendment No. 3 to the Fifth Amended and Restated Advisory Agreement between Braemar Hotels and its advisor Ashford Inc., extending the negotiation period for revised Base Fee and Incentive Fee terms through December 31, 2026. While this is a material definitive agreement amendment affecting the company's advisory fee structure, it does not fit cleanly into the more specific event categories (not M&A, not exec compensation, not a routine administrative change). The amendment's materiality lies in its potential impact on the company's operating costs and advisor relationship, warranting disclosure as a material event.
View raw filing on EDGAR →Wayfair held its Annual Meeting of stockholders and disclosed certified vote results on four proposals: election of nine directors, ratification of PricewaterhouseCoopers LLP as independent auditor, non-binding advisory approval of named executive officer compensation, and approval of Amendment No. 1 to the 2023 Incentive Award Plan increasing authorized shares by 20,000,000 for equity compensation purposes.
View raw filing on EDGAR →Booz Allen Hamilton disclosed results of operations for the fiscal year ended March 31, 2026, via a press release (Exhibit 99.1) and posted an earnings conference call presentation to its investor relations website (Exhibit 99.2) on May 22, 2026.
View raw filing on EDGAR →The filing discloses Item 5.07 results from Bunge Global SA's 2026 Annual General Meeting of Shareholders held on May 20, 2026, with detailed vote tabulations on 12 matters including approval of financial statements, director elections, board chair reelection, compensation approvals, and auditor appointment. This is a standard shareholder vote results disclosure that is material to investors as it confirms governance actions and executive compensation approvals.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the Company's Annual Meeting held on May 19, 2026. The filing reports voting outcomes on three proposals: election of directors (Patrick M. Covey, Jerome P. Grisko Jr., and Thomas A. Haught), advisory approval of named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditor. Item 5.07 is the designated 8-K item for shareholder vote results, and the prose directly presents vote tallies for each proposal.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting held on May 21, 2026, covering three matters: election of four directors, advisory vote on named executive officer compensation, and ratification of KPMG LLP as independent auditor. The filing presents detailed vote tallies for each matter, which is the core content of Item 5.07 disclosures and materially informs investors of governance outcomes.
View raw filing on EDGAR →Cavco Industries disclosed financial results for fiscal fourth quarter and full year ended March 28, 2026, with a press release attached as Exhibit 99.1.
View raw filing on EDGAR →The Board approved a $150 million stock repurchase program on May 18, 2026, representing a material capital allocation decision affecting shareholder value and the company's financial flexibility.
View raw filing on EDGAR →Ares Real Estate Income Trust amended its subscription agreement with Apogee SPV, an affiliate of the Company's advisor, whereby Apogee will purchase an additional $100 million in Class B Common Shares, bringing the total commitment to $300 million. This unregistered equity issuance represents a material capital transaction affecting the Company's capitalization and ownership structure.
View raw filing on EDGAR →The disclosure under Item 5.02(e) describes amendments to employment agreements for six executive officers (Bordelon, Guidry, Herpin, Kirkley, Lemoine, and Zollinger) that extend the terms of their existing agreements to 2028–2029. While the filing states "no other changes were made," the extension of employment agreements constitutes a material compensatory arrangement modification affecting named executives. This falls squarely within the exec_compensation category as a material arrangement affecting executive tenure and job security.
View raw filing on EDGAR →BlackSky entered into a Sales Agreement with Deutsche Bank Securities and Craig-Hallum Capital Group to offer and sell up to $250 million of Class A common stock through an "at the market offering" under Rule 415(a)(4). This is a classic ATM offering—a dilutive equity issuance that allows the company to raise capital by selling shares at market prices over time. The magnitude ($250M) and structure (registered direct offering through sales agents) are material to investors assessing shareholder dilution and the company's capital-raising strategy.
View raw filing on EDGAR →Ares Sports, Media & Entertainment Opportunities LP completed an unregistered private placement of approximately $27.5 million in limited partnership units to accredited investors and qualified purchasers under Section 4(a)(2) and Regulation D, bringing cumulative issuances to approximately $769 million.
View raw filing on EDGAR →Stockholders voted at the Annual Meeting held on May 21, 2026, approving the election of nine directors, advisory approval of named executive officer compensation, an amendment to the 2023 Equity Incentive Plan increasing authorized shares by 5,000,000 shares, and ratification of Deloitte & Touche LLP as independent auditor.
View raw filing on EDGAR →Merck closed a $5.5 billion underwritten public offering of debt securities across seven tranches (Floating Rate Notes, 2028, 2031, 2033, 2036, 2046, and 2056 Notes). While this is a material financing event affecting the company's capital structure and liquidity, it does not fit neatly into the specific taxonomy categories (not M&A, not a dilutive equity issuance, not a restatement or covenant breach). This is a significant debt issuance that would materially affect a reasonable investor's assessment of the registrant's financial position and leverage.
View raw filing on EDGAR →Jared Chomko was appointed as Principal Accounting Officer effective May 19, 2026, filling a position that had been vacant and filled on an interim basis by the CFO since October 2025. This appointment represents a material change in the company's financial reporting infrastructure and accounting leadership.
View raw filing on EDGAR →At Ibotta's May 19, 2026 annual meeting of shareholders, four proposals were submitted to a vote and all passed with substantial majorities: election of Class II directors Amit Doshi and Larry Sonsini, advisory approval of named executive officer compensation, annual frequency of say-on-pay votes, and ratification of KPMG as independent auditor.
View raw filing on EDGAR →RCI Hospitality received a written notice from Nasdaq on May 20, 2026 indicating non-compliance with Listing Rule 5250(c)(1) due to failure to file the Form 10-Q for Q1 2026. The company has until July 20, 2026 to submit a compliance plan and until November 16, 2026 to regain compliance by filing the overdue Form 10-Q. This is a classic delisting risk disclosure under Item 3.01, as it notifies investors of a failure to satisfy continued listing standards and the potential consequences if compliance is not restored.
View raw filing on EDGAR →Everspin held its Annual Meeting of Stockholders on May 21, 2026, with stockholders voting on four proposals: election of seven directors, ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amended equity incentive plan. The filing discloses complete tabulated vote results for each proposal.
View raw filing on EDGAR →Stockholders approved an amended and restated equity incentive plan that materially expands the share reserve by 1,800,000 shares and modifies the terms governing stock option and equity awards to directors and officers. This material amendment to the equity compensation plan was approved at the May 21, 2026 Annual Meeting.
View raw filing on EDGAR →